Compare IRMD & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | CMPX |
|---|---|---|
| Founded | 1992 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 927.5M |
| IPO Year | 2014 | 2020 |
| Metric | IRMD | CMPX |
|---|---|---|
| Price | $94.02 | $2.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | ★ $116.00 | $14.57 |
| AVG Volume (30 Days) | 99.5K | ★ 5.1M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.95% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $83,814,000.00 | N/A |
| Revenue This Year | $12.38 | N/A |
| Revenue Next Year | $11.31 | $934.41 |
| P/E Ratio | $202.49 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $55.11 | $1.61 |
| 52 Week High | $107.90 | $6.88 |
| Indicator | IRMD | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 39.05 |
| Support Level | $92.51 | $1.68 |
| Resistance Level | $97.36 | $3.82 |
| Average True Range (ATR) | 3.48 | 0.16 |
| MACD | 0.58 | 0.13 |
| Stochastic Oscillator | 90.62 | 52.04 |
iRadimed Corp develops, manufactures, markets, and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system, which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates the majority revenue from United States.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.